Opinion|Videos|August 14, 2024
Optimizing Anemia Management and Addressing Unmet Needs in LR MDS
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series
- Please share your key takeaways for optimizing anemia management in lower-risk MDS, and where do you see the most significant unmet needs?
- What remain the key unmet needs in treating anemia and improving outcomes for lower-risk MDS patients despite the availability of therapies like imetelstat, luspatercept, and ESAs?
- Are there any emerging agents, combination regimens, or ongoing trials in the pipeline?
Advertisement
Related to this article
Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and dosimetry to alpha-emitting therapies.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
3
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5